AKBA
Price
$1.37
Change
+$0.01 (+0.74%)
Updated
Apr 24, 6:59 PM EST
11 days until earnings call
MORF
Price
$27.69
Change
-$1.06 (-3.69%)
Updated
Apr 24, 6:59 PM EST
Earnings call today
Ad is loading...

Compare trend and price AKBA vs MORF

Header iconAKBA vs MORF Comparison
Open Charts AKBA vs MORFBanner chart's image
Akebia Therapeutics
Price$1.37
Change+$0.01 (+0.74%)
Volume$910.79K
CapitalizationN/A
Morphic Holding
Price$27.69
Change-$1.06 (-3.69%)
Volume$186.28K
CapitalizationN/A
View a ticker or compare two or three
AKBA vs MORF Comparison Chart

Loading...

AKBADaily Signal changed days agoGain/Loss if shorted
 
Show more...
MORFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AKBA vs. MORF commentary
Apr 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and MORF is a Hold.

COMPARISON
Comparison
Apr 25, 2024
Stock price -- (AKBA: $1.37 vs. MORF: $28.75)
Brand notoriety: AKBA and MORF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 35% vs. MORF: 123%
Market capitalization -- AKBA: $286.84M vs. MORF: $1.39B
AKBA [@Biotechnology] is valued at $286.84M. MORF’s [@Biotechnology] market capitalization is $1.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $567.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.55B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileMORF’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • MORF’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than MORF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 3 TA indicator(s) are bullish while MORF’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 3 bullish, 7 bearish.
  • MORF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MORF is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а -2.14% price change this week, while MORF (@Biotechnology) price change was +3.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.41%. For the same industry, the average monthly price growth was -3.09%, and the average quarterly price growth was +1263.37%.

Reported Earning Dates

AKBA is expected to report earnings on Aug 01, 2024.

MORF is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Biotechnology (+0.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AKBA with price predictions.
OPEN
A.I.dvisor published
a Summary for MORF with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MORF($1.44B) has a higher market cap than AKBA($287M). AKBA YTD gains are higher at: 10.484 vs. MORF (-0.450).
AKBAMORFAKBA / MORF
Capitalization287M1.44B20%
EBITDAN/AN/A-
Gain YTD10.484-0.450-2,329%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
4
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
46
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBAMORF
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 15 days ago
85%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
Bearish Trend about 1 month ago
83%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
AKBADaily Signal changed days agoGain/Loss if shorted
 
Show more...
MORFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PLAAX15.050.29
+1.96%
PACE Large Co Growth Equity A
USAAX34.420.54
+1.59%
Victory Growth
BFSIX22.160.32
+1.47%
BFS Equity Institutional
MIEIX33.660.34
+1.02%
MFS International Equity R6
EDIAX10.640.09
+0.85%
Eaton Vance Global Income Builder A

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with AVIR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then AVIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+0.74%
AVIR - AKBA
34%
Loosely correlated
+1.63%
VCYT - AKBA
33%
Poorly correlated
-0.10%
PRME - AKBA
32%
Poorly correlated
+0.42%
PHAT - AKBA
31%
Poorly correlated
+0.55%
CRSP - AKBA
31%
Poorly correlated
+1.35%
More

MORF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MORF has been loosely correlated with ORMP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MORF jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MORF
1D Price
Change %
MORF100%
+0.88%
ORMP - MORF
45%
Loosely correlated
+0.86%
AXON - MORF
43%
Loosely correlated
+2.64%
ARRY - MORF
42%
Loosely correlated
+2.14%
SRPT - MORF
42%
Loosely correlated
+0.14%
EDIT - MORF
41%
Loosely correlated
-2.50%
More